IRIS
ARCAINI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.620
EU - Europa 3.186
AS - Asia 2.345
Continente sconosciuto - Info sul continente non disponibili 10
SA - Sud America 9
OC - Oceania 8
AF - Africa 5
Totale 10.183
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.575
CN - Cina 1.937
IE - Irlanda 1.115
FI - Finlandia 441
UA - Ucraina 414
IT - Italia 390
SG - Singapore 301
DE - Germania 261
SE - Svezia 188
FR - Francia 181
GB - Regno Unito 111
IN - India 50
CA - Canada 40
BE - Belgio 28
JP - Giappone 19
RU - Federazione Russa 16
IR - Iran 13
TR - Turchia 10
AU - Australia 8
EU - Europa 8
NL - Olanda 7
BR - Brasile 6
LT - Lituania 5
RO - Romania 5
AT - Austria 4
PL - Polonia 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
CZ - Repubblica Ceca 3
IL - Israele 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BD - Bangladesh 2
CL - Cile 2
ID - Indonesia 2
LV - Lettonia 2
MU - Mauritius 2
MY - Malesia 2
NG - Nigeria 2
SK - Slovacchia (Repubblica Slovacca) 2
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
ES - Italia 1
HK - Hong Kong 1
HR - Croazia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MD - Moldavia 1
MS - Montserrat 1
MX - Messico 1
NO - Norvegia 1
PT - Portogallo 1
Totale 10.183
Salva come PNG Salva come JPEG
Città #
Dublin 1.112
Chandler 1.029
Jacksonville 580
Nanjing 523
Boardman 361
Ashburn 332
Singapore 224
Princeton 223
Lawrence 205
Nanchang 201
Wilmington 185
Beijing 177
Hebei 172
Helsinki 154
Medford 144
Shenyang 139
Changsha 137
Ann Arbor 130
Jiaxing 122
New York 111
Shanghai 99
Tianjin 92
Hangzhou 71
Milan 60
Pavia 59
Los Angeles 45
Seattle 42
Pune 40
Woodbridge 36
Falls Church 35
Norwalk 33
Brussels 28
Washington 23
Toronto 22
Verona 22
Fairfield 16
Tokyo 16
Zhengzhou 16
San Francisco 14
Brescia 13
Des Moines 13
Guangzhou 13
Chicago 11
Paris 11
Auburn Hills 10
Falkenstein 10
Jinan 10
Renton 10
Santa Clara 9
Kunming 8
London 8
Fuzhou 7
Houston 7
Ningbo 7
Redwood City 7
Genoa 6
Lanzhou 6
Rome 6
Xi'an 6
Frankfurt am Main 5
Taizhou 5
Tappahannock 5
Varese 5
Berlin 4
Brossard 4
Dallas 4
Istanbul 4
Leawood 4
Melbourne 4
Redmond 4
Shijiazhuang 4
Wuhan 4
Brugherio 3
Chongqing 3
Cork 3
Dubai 3
Florence 3
Giessen 3
Haikou 3
Jaguariúna 3
Las Vegas 3
Lugano 3
Monmouth Junction 3
Novokuznetsk 3
Nuremberg 3
Raffadali 3
San Salvador 3
Zanjan 3
Zhoukou 3
Ancona 2
Aprilia 2
Ardabil 2
Bergamo 2
Bologna 2
Borgomanero 2
Bronx 2
Casatenovo 2
Castelverde 2
Cerignola 2
Changzhou 2
Totale 7.337
Salva come PNG Salva come JPEG
Nome #
Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study 166
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 96
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 96
FLIPI2: A New Prognostic Index For Follicular Lymphoma Developed By The International Follicular Lymphoma Prognostic Factor Project (IFLPFP) 94
Splenic nodal and extranodal marginal zone lymphoma: features of bone marrow involvement. 87
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 85
Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients 84
Antibiotic therapy-induced remission of bladder mucosa-associated lymphoid tissue (MALT) lymphoma carrying t(11;18)(q21;q21) apoptosis inhibitor 2-MALT1. 83
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 81
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 80
B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution 79
Blast phase of essential thrombocythemia: A single center study. 78
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 75
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 73
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and nontoxic treatment for advanced follicular and mantle cell lymphoma 73
An insidious presentation of splenic marginal zone lymphoma 73
Absence of MYD88 L265P mutation in blastic plasmacytoid dendritic cell neoplasm 73
CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case 70
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 70
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 69
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection 69
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 68
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 68
Transient response of myeloma clone to pamidronate therapy 68
Pharmacokinetic behavior of Rituximab: a study of different schedules of administration for heterogeneous clinical settings. 67
A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma 67
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 67
Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. 67
Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives 65
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers 65
Depletion of circulating IgM memory B cells predicts unfavourable outcome in COVID-19 64
Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. 63
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 62
Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features. 62
Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. 62
Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection. 62
A young woman with microcytic anemia and hypertransaminasemia 62
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 61
Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse 61
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 61
Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk 61
Splenic marginal zone lymphoma: hydra with many heads? 60
Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. 60
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 60
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia 60
MYD88 L265P somatic mutation in Waldenstrom’s Macroglobulinemia 60
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 60
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 59
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma 59
Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. 59
Role of the molecular staging and response in the management of follicular lymphoma patients 58
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 58
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy 58
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 58
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 58
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 58
Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease 57
R-CVP vs R-CHOP vs R-FM for the initial treatment of patients with advanced stage Follicular Lymphoma. Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi (FIL) 57
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms 57
The krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. 57
Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection 56
Everolimus in diffuse large B-cell lymphomas 56
The NOTCH pathway is recurrently mutated in diffuse large B cell lymphoma associated with hepatitis C virus infection. 56
Effects of breathing control on cardiocirculatory modulation in Caucasian lowlanders and Himalayan Sherpas 55
Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities. 55
Risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy: development and validation on 593 cases 55
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. 55
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. 55
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 55
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 54
A paraumbilical lymphomatous mass 54
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). 54
Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies. 54
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma 54
Antiviral therapies for managing viral hepatitis in lymphoma patients 54
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction 54
Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up 54
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial 54
Reduced hypoxic ventilatory response with preserved blood oxygenation in yoga trainees and Himalayan Buddhist monks at altitude: evidence of a different adaptive strategy? 53
Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease 53
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience 53
Il ruolo del trapianto autologo nei linfomi non-Hodgkin indolenti 53
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 53
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma 53
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 53
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. 52
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 52
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 52
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 52
Risk of second cancer in nongastric marginal zone B-cell lymphomas of MALT: a population-based study from Northern Italy 52
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 52
A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. 52
Immunochemotherapy with rituximab, vincristine and 5-days cyclophosphamide (R-CV) for heavily pretreated follicular lymphoma 52
Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas 52
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 51
Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. 51
Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. 51
Overview on the management of non-gastric MALT lymphomas 51
Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy 51
Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders 51
Totale 6.279
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.533
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.533
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020437 0 0 0 0 0 81 19 86 5 177 60 9
2020/20211.013 98 70 21 79 10 171 14 178 107 124 116 25
2021/2022976 22 5 19 15 38 55 19 56 54 40 141 512
2022/20233.025 281 198 21 242 282 321 27 178 1.274 29 112 60
2023/20241.425 147 236 60 99 107 406 34 88 12 53 75 108
2024/2025867 117 274 76 89 79 232 0 0 0 0 0 0
Totale 10.683